Our Team

Excellence Starts with People

Supported by continuous training and development, our group of highly qualified Researchers and Technicians ensures improvement and success every step of the way.

At Galileo Research, our multidisciplinary team combines over 40 years of expertise in laboratory activities, GLP compliance, Quality Assurance and Business Development ensuring exceptional standards through open and innovative approaches to discovery and development. Driven by continuous professional development, we stay at the forefront of scientific advancements to provide cutting-edge solutions, offering clients the highest quality service and tailored support.

Silvia Trasciatti, Chief Scientific Officer, Chief Operations Officer, GLP Testing Facility Director

Silvia Trasciatti is a leading expert in pharmacology, toxicology, and molecular biology. With an impressive background spanning Biological Sciences, Biotechnology, and Business Economics, she played a pivotal role in developing Alendronate and advancing groundbreaking oncology therapies. A driving force behind over 15 clinical projects and 14 patents, she has secured 8 major research grants, shaping the future of allogeneic cell therapy in oncology with unwavering dedication and scientific excellence.

Dr. Paolo Baroldi, Board Member

Paolo Baroldi is a physician and clinical pharmacologist with over 35 years of experience in pharmaceutical medicine and drug development. He has contributed to groundbreaking medicines like Ritonavir and Imatinib. His extensive career spans roles from junior clinical pharmacologist at Farmitalia to senior management at Novartis, Chiesi, and Vanda, across multiple therapeutic areas, including CNS, CVS, urology, gastroenterology, diabetes, pulmonology, transplantation, oncology, infectious diseases, and endocrine disorders. Currently, he serves as Chief Medical Officer at Bloom Science Inc., San Diego, leading innovative drug development teams to bring scientific breakthroughs to the market.

Gianluca L’Abbate, Head of Business Development

Gianluca L’Abbate is a Senior professional with over 25 years of experience in Life Sciences. Since 1998, he has led pioneering pharmacological research, mastering in vivo and in vitro studies to evaluate new products' pharmacological activity. His extensive expertise allows him to oversee projects with a holistic view, optimizing all aspects and providing the best development and process solutions. He looks after Business Development and Commercial Operations, with a special eye focusing on scientific and technical aspects.

Lorenzo Pellegrini Quarantotti, Business Development & Commercial Operations

Lorenzo Pellegrini Quarantotti holds an Executive MBA from IMD, University of Lausanne. With 26 years of experience in International Sales, Business Development, and Commercial Operations in the bio-pharmaceutical and healthcare sectors, he has led significant high-value projects from R&D to business realization in several Organizations. He has managed institutional relations with major health organizations and participated in three successful start-ups, raising over $60M. Since May 2024 he forms part of Galileo Research BD&CO Team.

Francesca Piras, Deputy CSO, Head of R&D Laboratories

Francesca Piras holds a degree in Biological Science from the University of Pisa. With over 30 years of experience, she has worked in R&D Toxicology at Istituto Gentili, Abiogen Pharma, and now Galileo Research. As Deputy CSO and Study Director, she leads regulatory toxicology studies in line with FDA and OECD/ICH guidelines. Her expertise includes developing animal models for human diseases and reviewing CTDs for toxicology, contributing significantly to the drug development process and ensuring compliance with the latest standards.

Study Management Team

Elena Biasci, Research Technologist, Molecular Biology Specialist

Elena Biasci holds a bachelor's degree in Biomedical Laboratory Techniques (University of Pisa) with a background in clinical biochemistry. Since 1998, she has worked in R&D Molecular Biology, now at Galileo Research, gaining expertise in advanced technologies. Currently, she serves as Study Director for in vitro cytotoxicity, irritation, and biodegradation tests under OECD and ISO guidelines, contributing to new drug development.

Duccio Fratta, Researcher, Genotoxicity Specialist

Duccio Fratta holds a degree in Biological Science (University of Pisa) and has over 30 years of expertise in genetic toxicology and cell culture models. Since 1993, he has specialized in genotoxicity and carcinogenicity studies (in vitro/in vivo) at Istituto Gentili, later Abiogen Pharma, now Galileo Research. As Study Director, he leads GLP-compliant studies under FDA and OECD/ICH guidelines, advancing drug safety assessment and innovative disease models.

Sandra Marini, Senoir Scientist, ADME Specialist

Sandra Marini holds a degree in Biological Science (University of Pisa) and a Ph.D. in Pharmacology and Toxicology (University of Siena). With deep expertise in Phase I and II drug metabolism enzymes in hepatic and extrahepatic tissues, she gained extensive experience during a nine-year fellowship at CNR Pisa. Since 2004, she has worked in R&D Toxicology at Abiogen Pharma, now Galileo Research. As Study Director, she leads GLP-compliant ADME and single-dose toxicity studies under FDA and OECD/ICH guidelines, contributing to new drug development with advanced metabolism and disease models.

Simona Nencioni, Researcher

Simona Nencioni holds a degree in Biological Science (University of Pisa), a Ph.D. in Medical Sciences (Sant’Anna School of Advanced Studies, Pisa), and a Specialization in Clinical Biochemistry. With expertise in drug metabolism enzymes and genomic physiology, she gained significant experience at CNR Pisa. Since 2007, she has worked in R&D Molecular Biology at Abiogen Pharma, now Galileo Research. As Study Director, she leads GLP-compliant cytotoxicity, irritation, and biodegradation studies under OECD and ISO guidelines, applying advanced molecular biology techniques to support new drug development.